首页 > 最新文献

Journal of Pharmaceutical Policy and Practice最新文献

英文 中文
Exploring barriers and enablers of antibiotic amnesty campaigns. 探索抗生素大赦运动的障碍和推动因素。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-29 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2316033
Philip Howard, Gillian Hawksworth, Sara Hussain, Nafeesa Khan, Rabiya Bahadar, Jill Msindo, Sarah Frank, Mamoon A Aldeyab

This editorial highlights the different barriers and enablers of antibiotic amnesty campaigns in community pharmacies. The main enablers of antibiotic amnesties included effective counselling and successful use of promotional resources, whilst the main barriers included lack of education in patients and staff. Enabling factors such as effective counselling and use of promotional resources should be continued with patients, whilst the main barriers can be tackled with provision of sufficient education, training, and knowledge for patients. Educating staff, by providing appropriate training to all staff members present in the pharmacy, can positively contribute to the success of antibiotic amnesty campaigns. The findings of this work can inform the development of interventions needed to improve antibiotic amnesties, resulting in more antibiotics being returned and contributing towards tackling the issue of antimicrobial resistance (AMR).

这篇社论强调了社区药房开展抗生素特赦活动的不同障碍和促进因素。抗生素特赦的主要促进因素包括有效的咨询和宣传资源的成功使用,而主要障碍则包括缺乏对患者和员工的教育。应继续为患者提供有效咨询和使用宣传资源等有利因素,而主要障碍则可通过为患者提供足够的教育、培训和知识来解决。通过为药房的所有工作人员提供适当的培训来教育工作人员,可以为抗生素大赦运动的成功做出积极贡献。这项工作的发现可以为制定改善抗生素特赦所需的干预措施提供信息,从而使更多抗生素被退回,并为解决抗菌素耐药性(AMR)问题做出贡献。
{"title":"Exploring barriers and enablers of antibiotic amnesty campaigns.","authors":"Philip Howard, Gillian Hawksworth, Sara Hussain, Nafeesa Khan, Rabiya Bahadar, Jill Msindo, Sarah Frank, Mamoon A Aldeyab","doi":"10.1080/20523211.2024.2316033","DOIUrl":"10.1080/20523211.2024.2316033","url":null,"abstract":"<p><p>This editorial highlights the different barriers and enablers of antibiotic amnesty campaigns in community pharmacies. The main enablers of antibiotic amnesties included effective counselling and successful use of promotional resources, whilst the main barriers included lack of education in patients and staff. Enabling factors such as effective counselling and use of promotional resources should be continued with patients, whilst the main barriers can be tackled with provision of sufficient education, training, and knowledge for patients. Educating staff, by providing appropriate training to all staff members present in the pharmacy, can positively contribute to the success of antibiotic amnesty campaigns. The findings of this work can inform the development of interventions needed to improve antibiotic amnesties, resulting in more antibiotics being returned and contributing towards tackling the issue of antimicrobial resistance (AMR).</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The caregiver's experience of childhood cancer treatment in South Africa. 南非儿童癌症治疗护理者的经历。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-29 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2312382
I R Joosse, H A van den Ham, A K Mantel-Teeuwisse, F Suleman

Background: This study explored the treatment-related, financial and psychological experiences of caregivers during cancer treatment of their children in South Africa's (SA) public and private sectors.

Methods: In this exploratory study, three focus groups were conducted with caregivers of children undergoing cancer treatment in SA's public healthcare sector. A fourth small focus group with two parents in the private sector was conducted online. A mixed-methods approach was employed using a combination of thematic analysis and grounded theory.

Results: Of the 20 public sector caregivers, many expressed frustration at the number of visits to primary healthcare clinics before being referred. Caregivers had difficulties coping with and accepting the diagnosis, alongside managing continued care for the child and other children at home. Support received by family and community members was varied. Financial strain was an important concern. The two private sector parents indicated greater levels of support and no financial hardship, but expressed similar levels of emotional stress.

Conclusion: These caregiver experiences indicate that improvements are urgently needed in the recognition of childhood cancer symptoms at primary healthcare level in SA. They also highlight a need for increased financial support from government through social grants, travel allowances and nutritional support.

研究背景本研究探讨了南非(SA)公立和私立医疗机构儿童癌症治疗过程中照顾者在治疗相关、经济和心理方面的经历:在这项探索性研究中,我们与南非公立医疗机构中正在接受癌症治疗的儿童的照顾者进行了三次焦点小组讨论。第四个小型焦点小组是在网上进行的,有两名私立医疗机构的家长参加。研究采用了主题分析和基础理论相结合的混合方法:结果:在 20 名公共部门的照顾者中,许多人对在转诊前到初级保健诊所就诊的次数表示沮丧。照护者在应对和接受诊断结果以及继续照护孩子和家中其他孩子方面遇到了困难。家庭和社区成员提供的支持各不相同。经济压力是一个重要问题。两位私营企业的家长表示得到了更多的支持,没有经济困难,但也表达了类似程度的情绪压力:这些照顾者的经历表明,南澳大利亚初级医疗保健机构在识别儿童癌症症状方面亟需改进。他们还强调,政府需要通过社会补助金、交通补贴和营养支持来增加经济支持。
{"title":"The caregiver's experience of childhood cancer treatment in South Africa.","authors":"I R Joosse, H A van den Ham, A K Mantel-Teeuwisse, F Suleman","doi":"10.1080/20523211.2024.2312382","DOIUrl":"10.1080/20523211.2024.2312382","url":null,"abstract":"<p><strong>Background: </strong>This study explored the treatment-related, financial and psychological experiences of caregivers during cancer treatment of their children in South Africa's (SA) public and private sectors.</p><p><strong>Methods: </strong>In this exploratory study, three focus groups were conducted with caregivers of children undergoing cancer treatment in SA's public healthcare sector. A fourth small focus group with two parents in the private sector was conducted online. A mixed-methods approach was employed using a combination of thematic analysis and grounded theory.</p><p><strong>Results: </strong>Of the 20 public sector caregivers, many expressed frustration at the number of visits to primary healthcare clinics before being referred. Caregivers had difficulties coping with and accepting the diagnosis, alongside managing continued care for the child and other children at home. Support received by family and community members was varied. Financial strain was an important concern. The two private sector parents indicated greater levels of support and no financial hardship, but expressed similar levels of emotional stress.</p><p><strong>Conclusion: </strong>These caregiver experiences indicate that improvements are urgently needed in the recognition of childhood cancer symptoms at primary healthcare level in SA. They also highlight a need for increased financial support from government through social grants, travel allowances and nutritional support.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-reported side effects of COVID-19 vaccines among the public. 公众对 COVID-19 疫苗副作用的自我报告。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-27 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2308617
Mahmathi Karuppannan, Long Chiau Ming, Mohd Shahezwan Abdul Wahab, Zakiah Mohd Noordin, Shermaine Yee, Andi Hermansyah

Background: The safety, side effects and efficacy profile of COVID-19 vaccines remain subjects of ongoing concern among the public in Malaysia. The aim of this study was to determine the types of adverse effects following immunisation with COVID-19 vaccines and the differences based on various types of COVID-19 vaccines to raise public awareness and reduce vaccine hesitancy among the public.

Methods: A total of 901 Malaysian adults (≥18 years) who received various COVID-19 vaccines were selected to participate in our cross-sectional study through an online survey between December 2021 and January 2022.

Results: A total of 814 (90.3%) of the participants reported ≥1 side effect following COVID-19 immunisation. Of these, the predominant symptoms were swelling at the injection site (n = 752, 83.5%), headache (n = 638, 70.8%), pain or soreness at the injection site (n = 628, 69.7%), fatigue or tiredness (n = 544, 60.4%), muscle weakness (n = 529, 58.7%) and diarrhea (n = 451, 50.1%). Recipients of the Pfizer-BioNTech (Comirnaty ®) vaccine reported the highest number of adverse effects (n = 355, 43.6%), followed by mixed COVID-19 vaccines (n = 254, 31.2%), the Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine (n = 113, 13.9%) and the Sinovac (CoronaVac®) vaccine (n = 90, 11.1%). The study showed that individuals who reported significantly more side effects were of elderly age, female gender and high educational level [P value < 0.05]. Mixed COVID-19 vaccine recipients also reported significantly more local and systemic symptoms after the first dose and third dose when compared with other single vaccine recipients.

Conclusion: This study demonstrated the types of self-reported adverse effects following immunisation with single and mixed COVID-19 vaccines. These findings may provide the side effects of different COVID-19 vaccines with the hope of educating the public on the safety profiles of these vaccines and reducing vaccine hesitancy among the public.

背景:COVID-19 疫苗的安全性、副作用和效力状况仍然是马来西亚公众持续关注的问题。本研究旨在确定接种 COVID-19 疫苗后的不良反应类型以及不同类型 COVID-19 疫苗的差异,以提高公众意识,减少公众对疫苗的犹豫:方法:在2021年12月至2022年1月期间,我们通过在线调查的方式共选取了901名接种过各种COVID-19疫苗的马来西亚成年人(≥18岁)参与横断面研究:结果:共有814名参与者(90.3%)在接种COVID-19疫苗后报告了≥1种副作用。其中,主要症状为注射部位肿胀(752人,83.5%)、头痛(638人,70.8%)、注射部位疼痛或酸痛(628人,69.7%)、疲劳或倦怠(544人,60.4%)、肌肉无力(529人,58.7%)和腹泻(451人,50.1%)。辉瑞-生物技术公司(Comirnaty ®)疫苗的接种者报告的不良反应最多(355人,43.6%),其次是COVID-19混合疫苗(254人,31.2%)、牛津-阿斯利康公司(ChAdOx1-®[重组])疫苗(113人,13.9%)和Sinovac(CoronaVac®)疫苗(90人,11.1%)。研究显示,报告副作用明显较多的人群年龄偏大、性别为女性且受教育程度较高[P 值 结论:本研究显示了接种单一和混合 COVID-19 疫苗后自我报告的不良反应类型。这些发现可提供不同 COVID-19 疫苗的副作用,希望能让公众了解这些疫苗的安全性,减少公众对疫苗的犹豫。
{"title":"Self-reported side effects of COVID-19 vaccines among the public.","authors":"Mahmathi Karuppannan, Long Chiau Ming, Mohd Shahezwan Abdul Wahab, Zakiah Mohd Noordin, Shermaine Yee, Andi Hermansyah","doi":"10.1080/20523211.2024.2308617","DOIUrl":"10.1080/20523211.2024.2308617","url":null,"abstract":"<p><strong>Background: </strong>The safety, side effects and efficacy profile of COVID-19 vaccines remain subjects of ongoing concern among the public in Malaysia. The aim of this study was to determine the types of adverse effects following immunisation with COVID-19 vaccines and the differences based on various types of COVID-19 vaccines to raise public awareness and reduce vaccine hesitancy among the public.</p><p><strong>Methods: </strong><i>A total of</i> 901 Malaysian adults (≥18 years) who received various COVID-19 vaccines were selected to participate in our cross-sectional study through an online survey between December 2021 and January 2022.</p><p><strong>Results: </strong><i>A total of</i> 814 (90.3%) of the participants reported ≥1 side effect following COVID-19 immunisation. Of these, the predominant symptoms were swelling at the injection site (<i>n</i> = 752, 83.5%), headache (<i>n</i> = 638, 70.8%), pain or soreness at the injection site (<i>n</i> = 628, 69.7%), fatigue or tiredness (<i>n</i> = 544, 60.4%), muscle weakness (<i>n</i> = 529, 58.7%) and diarrhea (<i>n</i> = 451, 50.1%). Recipients of the Pfizer-BioNTech (Comirnaty ®) vaccine reported the highest number of adverse effects (<i>n</i> = 355, 43.6%), followed by mixed COVID-19 vaccines (<i>n</i> = 254, 31.2%), the Oxford-AstraZeneca (ChAdOx1-®[recombinant]) vaccine (<i>n</i> = 113, 13.9%) and the Sinovac (CoronaVac®) vaccine (<i>n</i> = 90, 11.1%). The study showed that individuals who reported significantly more side effects were of elderly age, female gender and high educational level [<i>P</i> value < 0.05]. Mixed COVID-19 vaccine recipients also reported significantly more local and systemic symptoms after the first dose and third dose when compared with other single vaccine recipients.</p><p><strong>Conclusion: </strong>This study demonstrated the types of self-reported adverse effects following immunisation with single and mixed COVID-19 vaccines. These findings may provide the side effects of different COVID-19 vaccines with the hope of educating the public on the safety profiles of these vaccines and reducing vaccine hesitancy among the public.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10901186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-hospital outcome and its predictors among patients with acute cardiogenic pulmonary oedema at a tertiary hospital in Harar, Eastern Ethiopia: a retrospective cohort study 埃塞俄比亚东部哈拉尔一家三级医院急性心源性肺水肿患者的院内预后及其预测因素:一项回顾性队列研究
IF 4.2 Q1 Health Professions Pub Date : 2024-02-22 DOI: 10.1080/20523211.2024.2309294
Natanim Degefu, A. Jambo, Lemma Demissie Regassa, Melaku Getachew
ABSTRACT Background: Acute cardiogenic pulmonary oedema is highly associated with poor in-hospital outcomes. This study aimed to determine the in-hospital outcome and its predictors among patients with acute cardiogenic pulmonary oedema at a tertiary hospital in Harar, Eastern Ethiopia, from May 1 to 20, 2023. Methods: A retrospective cohort study was employed among 204 patients with acute cardiogenic pulmonary oedema who were admitted between 1st May 2018 and 30th April 2023. The collected data were entered into Excel, and analysed using theSTATA software version 17. The hazard ratio with its 95% confidence interval was used and a P-value < 0.05 was considered a statistically significant association. Results: The overall mortality rate was 17.60 (95% CI: 11.59–26.72) per 1000 person-day observation with mean (±SD) time to death was 2.88 (±2.06) days. Age (AHR: 1.35; 95% CI: 1.04–1.74 for every 10 years), being smoker (AHR: 3.26; 95% CI: 1.05–10.10), having respiratory rate of ≥40 breaths per minute (AHR: 5.46; 95% CI: 1.71–17.45), and having anaemia (AHR: 4.35; 95% CI: 1.23–15.33) were significant predictors of in-hospital mortality. Conclusion: More than one in ten patients in this study died in the hospital. Therefore, special attention needs to be considered for patients with those predictors of in-hospital mortality.
摘要 背景:急性心源性肺水肿与不良的院内预后密切相关。本研究旨在确定埃塞俄比亚东部哈拉尔一家三级医院 2023 年 5 月 1 日至 20 日期间急性心源性肺水肿患者的院内预后及其预测因素。研究方法对2018年5月1日至2023年4月30日期间收治的204名急性心源性肺水肿患者进行回顾性队列研究。收集的数据输入Excel,并使用STATA软件17版进行分析。使用危险比及其95%置信区间,P值小于0.05视为有统计学意义的关联。结果总死亡率为每千人观察日 17.60(95% CI:11.59-26.72),平均(±SD)死亡时间为 2.88(±2.06)天。年龄(AHR:1.35;95% CI:每 10 年 1.04-1.74)、吸烟(AHR:3.26;95% CI:1.05-10.10)、呼吸频率≥40 次/分钟(AHR:5.46;95% CI:1.71-17.45)和贫血(AHR:4.35;95% CI:1.23-15.33)是院内死亡率的重要预测因素。结论本研究中有超过十分之一的患者死于医院。因此,需要特别关注有这些院内死亡预测因素的患者。
{"title":"In-hospital outcome and its predictors among patients with acute cardiogenic pulmonary oedema at a tertiary hospital in Harar, Eastern Ethiopia: a retrospective cohort study","authors":"Natanim Degefu, A. Jambo, Lemma Demissie Regassa, Melaku Getachew","doi":"10.1080/20523211.2024.2309294","DOIUrl":"https://doi.org/10.1080/20523211.2024.2309294","url":null,"abstract":"ABSTRACT Background: Acute cardiogenic pulmonary oedema is highly associated with poor in-hospital outcomes. This study aimed to determine the in-hospital outcome and its predictors among patients with acute cardiogenic pulmonary oedema at a tertiary hospital in Harar, Eastern Ethiopia, from May 1 to 20, 2023. Methods: A retrospective cohort study was employed among 204 patients with acute cardiogenic pulmonary oedema who were admitted between 1st May 2018 and 30th April 2023. The collected data were entered into Excel, and analysed using theSTATA software version 17. The hazard ratio with its 95% confidence interval was used and a P-value < 0.05 was considered a statistically significant association. Results: The overall mortality rate was 17.60 (95% CI: 11.59–26.72) per 1000 person-day observation with mean (±SD) time to death was 2.88 (±2.06) days. Age (AHR: 1.35; 95% CI: 1.04–1.74 for every 10 years), being smoker (AHR: 3.26; 95% CI: 1.05–10.10), having respiratory rate of ≥40 breaths per minute (AHR: 5.46; 95% CI: 1.71–17.45), and having anaemia (AHR: 4.35; 95% CI: 1.23–15.33) were significant predictors of in-hospital mortality. Conclusion: More than one in ten patients in this study died in the hospital. Therefore, special attention needs to be considered for patients with those predictors of in-hospital mortality.","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139957770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of prescription patterns on the performance of the pharmacy department of a Regional Referral Hospital, Uganda. 处方模式对乌干达地区转诊医院药剂部工作的影响。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-20 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2306852
Gerald Manzi Mbabazize, Vedaste Kagisha, Kato J Njunwa, Joseph Oloro

Background: Poor drug prescription patterns (PP) result in irrational medicine use, avoidable stock outs and drug expiries.

Objective: This study primarily assessed the effects of PP on the performance of the pharmacy department (PD) of Mbarara Regional Referral Hospital (MRRH) Uganda.

Methods: This was a mixed method cross-sectional study conducted in the outpatient department (OPD) of MRRH, questionnaires were administered to 86 prescribers and 300 patient prescriptions were reviewed. Ethical clearance was granted and informed consent of patients. Data were analysed, presented in the form of graphs, tables.

Results: The overall prescription fill rate was 60.5%, being higher among dental officers and lower among those who did not adhere to generic prescribing and EML. Medical officers made most prescriptions at 69.3%. Prescriptions with four (47.1%) and six (17.5%) medicines respectively were made by clinical officers. Of the 300 prescriptions, 76% adhered to the Essential Medicines List (EML), 62% used generic name including 87.3% from dental officers and 52.9% by clinical officersThe overall prescription fill rate was 60.5%, being higher among dental officers and lower among those who did not adhere to generic prescribing and EML. Medical officers made most prescriptions at 69.3%. Prescriptions with four (47.1%) and six (17.5%) medicines respectively were made by clinical officers. Of the 300 prescriptions, 76% adhered to the Essential Medicines List (EML), 62% used generic name including 87.3% from dental officers and 52.9% by clinical officers.

Conclusion: Prescription pattern affected the performance of the PD of MRRH, calling for its continued monitoring to ensure that guidelines are upheld, EML and UCG are availed and utilized.

背景不良的药品处方模式(PP)会导致不合理用药、可避免的缺货和药品过期:本研究主要评估了药品处方对乌干达姆巴拉拉地区转诊医院(MRRH)药剂科工作的影响:这是一项在姆巴拉拉地区转诊医院门诊部(OPD)进行的混合横断面研究,对 86 名处方人员进行了问卷调查,并对 300 份患者处方进行了审查。研究获得了伦理许可和患者的知情同意。对数据进行了分析,并以图表的形式呈现:结果:总体处方开具率为 60.5%,牙科医师的处方开具率较高,而不遵守非专利处方和 EML 的医师的处方开具率较低。医务人员开出的处方最多,占 69.3%。临床医护人员分别开具了 4 种(47.1%)和 6 种(17.5%)药品的处方。在 300 份处方中,76%符合基本药物目录(EML),62%使用通用名,其中 87.3%来自牙医,52.9%来自临床医生。医务人员开出的处方最多,占 69.3%。临床医护人员分别开具了 4 种(47.1%)和 6 种(17.5%)药品的处方。在 300 份处方中,76%符合基本药物目录(EML),62%使用通用名,其中 87.3%来自牙科医生,52.9%由临床医生开具:结论:处方模式影响了 MRRH PD 的工作表现,因此需要对其进行持续监测,以确保遵守相关准则、使用 EML 和 UCG。
{"title":"The effect of prescription patterns on the performance of the pharmacy department of a Regional Referral Hospital, Uganda.","authors":"Gerald Manzi Mbabazize, Vedaste Kagisha, Kato J Njunwa, Joseph Oloro","doi":"10.1080/20523211.2024.2306852","DOIUrl":"10.1080/20523211.2024.2306852","url":null,"abstract":"<p><strong>Background: </strong>Poor drug prescription patterns (PP) result in irrational medicine use, avoidable stock outs and drug expiries.</p><p><strong>Objective: </strong>This study primarily assessed the effects of PP on the performance of the pharmacy department (PD) of Mbarara Regional Referral Hospital (MRRH) Uganda.</p><p><strong>Methods: </strong>This was a mixed method cross-sectional study conducted in the outpatient department (OPD) of MRRH, questionnaires were administered to 86 prescribers and 300 patient prescriptions were reviewed. Ethical clearance was granted and informed consent of patients. Data were analysed, presented in the form of graphs, tables.</p><p><strong>Results: </strong>The overall prescription fill rate was 60.5%, being higher among dental officers and lower among those who did not adhere to generic prescribing and EML. Medical officers made most prescriptions at 69.3%. Prescriptions with four (47.1%) and six (17.5%) medicines respectively were made by clinical officers. Of the 300 prescriptions, 76% adhered to the Essential Medicines List (EML), 62% used generic name including 87.3% from dental officers and 52.9% by clinical officersThe overall prescription fill rate was 60.5%, being higher among dental officers and lower among those who did not adhere to generic prescribing and EML. Medical officers made most prescriptions at 69.3%. Prescriptions with four (47.1%) and six (17.5%) medicines respectively were made by clinical officers. Of the 300 prescriptions, 76% adhered to the Essential Medicines List (EML), 62% used generic name including 87.3% from dental officers and 52.9% by clinical officers.</p><p><strong>Conclusion: </strong>Prescription pattern affected the performance of the PD of MRRH, calling for its continued monitoring to ensure that guidelines are upheld, EML and UCG are availed and utilized.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10880563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139931653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omicron wave during December 2022 - January 2023: access to pharmaceuticals and healthcare resources and impacts on health outcomes in Shenzhen, China. 2022 年 12 月至 2023 年 1 月期间的 Omicron 浪潮:中国深圳的药品和医疗资源获取情况及其对健康结果的影响。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-13 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2306867
Jiayue Chen, Haisu Feng, Jiatong Sun, Yawen Jiang

Purpose: This study described pharmaceutical and medical resource accessibility of COVID-19 treatment in Shenzhen, China during the peak of COVID-19 infection from December 2022 to January 2023, and examined its influence on clinical outcomes.

Methods: We surveyed Shenzhen residents on COVID-19-related topics using electronic questionnaires. We conducted descriptive statistical analyses and multiple regressions including logistic and Tobit models to explore the impacts of resource constraints on patient outcomes. Resource utilisation and attempts to seek medical care were also described for severity-stratified subgroups.

Results: 76.8% of respondents reported experiencing COVID-19 symptoms between December 7, 2022 and January 29, 2023. Of those who attempted to purchase medication, 72.8% reported drug shortage. 49% of those seeking medical treatment experienced difficulties. Compared with those who did not experience drug shortages, those who did had an odds ratio of 1.959 (95% CI: 1.159 ∼3.313) of presenting with moderate to severe symptoms. Compared with those without difficulties in seeking medical treatment, those who did had an average of 0.39 (95% CI: 0.110 ∼0.670) more days absent from work.

Conclusion: Shenzhen residents with COVID-19 symptoms from December 2022 to January 2023 experienced a certain degree of pharmaceutical and medical resource constraints, which might have compromised their prognosis.

目的:本研究描述了2022年12月至2023年1月COVID-19感染高峰期中国深圳COVID-19治疗的药品和医疗资源可及性,并探讨了其对临床结果的影响:我们使用电子问卷对深圳居民进行了COVID-19相关主题的调查。我们进行了描述性统计分析和多元回归,包括逻辑模型和 Tobit 模型,以探讨资源限制对患者预后的影响。此外,我们还对严重程度分层分组的资源利用率和求医尝试进行了描述:76.8%的受访者表示在2022年12月7日至2023年1月29日期间出现过COVID-19症状。在试图购买药物的受访者中,72.8%的人表示药物短缺。49%的求医者遇到了困难。与没有遇到药物短缺的人相比,遇到药物短缺的人出现中度至重度症状的几率比为 1.959(95% CI:1.159 ∼3.313)。与没有就医困难的居民相比,有就医困难的居民平均缺勤天数增加了 0.39 天(95% CI:0.110 ∼ 0.670):结论:2022 年 12 月至 2023 年 1 月期间,出现 COVID-19 症状的深圳居民经历了一定程度的药物和医疗资源限制,这可能会影响他们的预后。
{"title":"Omicron wave during December 2022 - January 2023: access to pharmaceuticals and healthcare resources and impacts on health outcomes in Shenzhen, China.","authors":"Jiayue Chen, Haisu Feng, Jiatong Sun, Yawen Jiang","doi":"10.1080/20523211.2024.2306867","DOIUrl":"10.1080/20523211.2024.2306867","url":null,"abstract":"<p><strong>Purpose: </strong>This study described pharmaceutical and medical resource accessibility of COVID-19 treatment in Shenzhen, China during the peak of COVID-19 infection from December 2022 to January 2023, and examined its influence on clinical outcomes.</p><p><strong>Methods: </strong>We surveyed Shenzhen residents on COVID-19-related topics using electronic questionnaires. We conducted descriptive statistical analyses and multiple regressions including logistic and Tobit models to explore the impacts of resource constraints on patient outcomes. Resource utilisation and attempts to seek medical care were also described for severity-stratified subgroups.</p><p><strong>Results: </strong>76.8% of respondents reported experiencing COVID-19 symptoms between December 7, 2022 and January 29, 2023. Of those who attempted to purchase medication, 72.8% reported drug shortage. 49% of those seeking medical treatment experienced difficulties. Compared with those who did not experience drug shortages, those who did had an odds ratio of 1.959 (95% CI: 1.159 ∼3.313) of presenting with moderate to severe symptoms. Compared with those without difficulties in seeking medical treatment, those who did had an average of 0.39 (95% CI: 0.110 ∼0.670) more days absent from work.</p><p><strong>Conclusion: </strong>Shenzhen residents with COVID-19 symptoms from December 2022 to January 2023 experienced a certain degree of pharmaceutical and medical resource constraints, which might have compromised their prognosis.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10866053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139735431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of pharmaceutical care interventions in improving clinical outcomes among patients with pulmonary tuberculosis: a systematic review. 药物护理干预对改善肺结核患者临床疗效的影响:系统综述。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-07 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2305770
Kheloud Awad, Myriam Jaam, Ahmed Awaisu, Derek Stewart, Hassaan Anwer Rathore, Muhammad Abdul Hadi

Background: Pharmacists can play an important role in the fight against tuberculosis (TB) through optimising medication use and safety, promoting adherence to anti-TB drugs, and providing patient education. Limited evidence is available on the effectiveness of pharmacist's interventions on health outcomes in patients with pulmonary TB. This systematic review aims to assess the effectiveness of pharmaceutical care interventions in the management of pulmonary TB.

Methods: English language studies assessing the impact of pharmaceutical care interventions in TB management were searched across three electronic databases (PubMed, Embase, Cochrane), a RCT registry ClinicalTrial.gov, a peer-reviewed journal 'The Lancet Infectious Diseases', and the references of retrieved articles. Interventions delivered by pharmacists alone or as part of multidisciplinary teams were included in the review. Data were extracted using the modified Cochrane EPOC standardised data collection tool. The Cochrane Risk of Bias 2 and the NIH quality assessment tools were used to assess the risk of bias among included studies. Data were synthesised narratively. (PROSPERO Protocol Registration CRD42022325771).

Results: Thirteen studies, including two randomised controlled trials (RCTs) with a total of 3886 patients were included. Many of the included studies had a high risk of bias and lacked cohert reporting of treatment outcomes. The most common pharmaceutical care interventions were education and counselling regarding adverse drug reactions and resolution of drug-related problems. Five studies showed a relatively high TB completion rate yet only one study reached the targeted treatment success goal of (>90%).

Conclusion: The current evidence suggests that pharmaceutical care interventions can potentially improve treatment outcomes among patients with pulmonary TB. However, no definitive conclusion can be drawn given the low methodological quality of the included studies and lack of long-term follow-up data. Well-designed RCTs with careful attention to study methodology, standardised outcomes assessment aligned with the World Health Organization's guidelines are warranted to guide future practice and policy.

背景:药剂师可以通过优化药物使用和安全性、促进患者坚持服用抗结核药物以及提供患者教育,在抗击结核病(TB)的斗争中发挥重要作用。关于药剂师的干预措施对肺结核患者健康结果的影响,目前证据有限。本系统性综述旨在评估药物治疗干预在肺结核治疗中的有效性:方法:在三个电子数据库(PubMed、Embase、Cochrane)、RCT 登记处 ClinicalTrial.gov、同行评审期刊《柳叶刀传染病》以及检索到的文章的参考文献中搜索了评估药物治疗干预在肺结核治疗中的影响的英文研究。由药剂师单独提供或作为多学科团队的一部分提供的干预措施均纳入审查范围。使用修改后的 Cochrane EPOC 标准化数据收集工具提取数据。采用 Cochrane Risk of Bias 2 和 NIH 质量评估工具评估纳入研究的偏倚风险。对数据进行了叙述性综合。(PROSPERO协议注册号为CRD42022325771):共纳入 13 项研究,包括两项随机对照试验 (RCT),共计 3886 名患者。纳入的许多研究存在较高的偏倚风险,并且缺乏对治疗结果的一致性报告。最常见的药物治疗干预措施是关于药物不良反应的教育和咨询以及解决药物相关问题。五项研究显示结核病治疗完成率相对较高,但只有一项研究达到了目标治疗成功率(>90%):目前的证据表明,药物护理干预有可能改善肺结核患者的治疗效果。然而,由于纳入研究的方法质量不高,且缺乏长期随访数据,因此无法得出明确结论。为了指导未来的实践和政策,有必要进行精心设计的 RCT 研究,并认真关注研究方法、符合世界卫生组织指导方针的标准化结果评估。
{"title":"Impact of pharmaceutical care interventions in improving clinical outcomes among patients with pulmonary tuberculosis: a systematic review.","authors":"Kheloud Awad, Myriam Jaam, Ahmed Awaisu, Derek Stewart, Hassaan Anwer Rathore, Muhammad Abdul Hadi","doi":"10.1080/20523211.2024.2305770","DOIUrl":"10.1080/20523211.2024.2305770","url":null,"abstract":"<p><strong>Background: </strong>Pharmacists can play an important role in the fight against tuberculosis (TB) through optimising medication use and safety, promoting adherence to anti-TB drugs, and providing patient education. Limited evidence is available on the effectiveness of pharmacist's interventions on health outcomes in patients with pulmonary TB. This systematic review aims to assess the effectiveness of pharmaceutical care interventions in the management of pulmonary TB.</p><p><strong>Methods: </strong>English language studies assessing the impact of pharmaceutical care interventions in TB management were searched across three electronic databases (PubMed, Embase, Cochrane), a RCT registry ClinicalTrial.gov, a peer-reviewed journal 'The Lancet Infectious Diseases', and the references of retrieved articles. Interventions delivered by pharmacists alone or as part of multidisciplinary teams were included in the review. Data were extracted using the modified Cochrane EPOC standardised data collection tool. The Cochrane Risk of Bias 2 and the NIH quality assessment tools were used to assess the risk of bias among included studies. Data were synthesised narratively. (PROSPERO Protocol Registration CRD42022325771).</p><p><strong>Results: </strong>Thirteen studies, including two randomised controlled trials (RCTs) with a total of 3886 patients were included. Many of the included studies had a high risk of bias and lacked cohert reporting of treatment outcomes. The most common pharmaceutical care interventions were education and counselling regarding adverse drug reactions and resolution of drug-related problems. Five studies showed a relatively high TB completion rate yet only one study reached the targeted treatment success goal of (>90%).</p><p><strong>Conclusion: </strong>The current evidence suggests that pharmaceutical care interventions can potentially improve treatment outcomes among patients with pulmonary TB. However, no definitive conclusion can be drawn given the low methodological quality of the included studies and lack of long-term follow-up data. Well-designed RCTs with careful attention to study methodology, standardised outcomes assessment aligned with the World Health Organization's guidelines are warranted to guide future practice and policy.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accessibility of malaria commodities in Geita District Council, mainland Tanzania: the experiences from healthcare providers and clients. 坦桑尼亚大陆盖塔区议会疟疾商品的可及性:医疗服务提供者和客户的经验。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-07 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2308611
Anna David, Omary Swalehe, Jean D' Amour Habagusenga, Stany Banzimana, Domina Asingizwe, Frank Chacky, Fabrizio Molteni

Background: Access to essential malaria commodities is a cornerstone in malaria control. However optimal availability and access to essential malaria commodities remain a challenge in Tanzania. Therefore, this study aimed to explore the factors affecting the accessibility of malaria commodities in Tanzania.

Methods: This was a mixed-method cross-sectional study using both quantitative and qualitative approaches. Data were collected between February and March 2023 from health facilities, health facility staff, and patients.

Results: Availability of malaria commodities in government health facilities was 100% for all items while in the private and faith-based facilities, this ranged from 10% to 80%. The reasons for stockouts in Government facilities were related to delayed and inadequate quantity delivery while in private facilities the main reason was the lack of cash for procurement. Both private facilities' clients and healthcare providers concurred that most people do not access complete treatment due to the high costs of prescribed medicines and poor stocking levels.

Conclusion: The availability, hence the accessibility, of malaria commodities in private and faith-based health facilities is still sub-optimal. Logistic management needs to be improved to eliminate stockouts and malaria commodities high costs need a permanent solution.

背景:获得基本疟疾商品是疟疾控制的基石。然而,在坦桑尼亚,基本疟疾商品的最佳可用性和可及性仍然是一项挑战。因此,本研究旨在探讨影响坦桑尼亚疟疾防治商品可及性的因素:这是一项混合方法横断面研究,采用了定量和定性两种方法。数据收集时间为 2023 年 2 月至 3 月,收集对象包括医疗机构、医疗机构工作人员和患者:在政府医疗机构中,所有疟疾防治用品的供应率均为100%,而在私人和宗教机构中,供应率从10%到80%不等。政府医疗机构缺货的原因与交货延迟和数量不足有关,而私营医疗机构缺货的主要原因是缺乏采购现金。私营机构的客户和医疗服务提供者都认为,由于处方药成本高昂和库存量不足,大多数人无法获得完整的治疗:结论:私立医疗机构和宗教医疗机构的疟疾药品供应情况仍未达到最佳水平,因此其可获得性也未达到最佳水平。需要改善物流管理,以消除缺货现象,而疟疾商品的高昂成本也需要一个永久性的解决方案。
{"title":"Accessibility of malaria commodities in Geita District Council, mainland Tanzania: the experiences from healthcare providers and clients.","authors":"Anna David, Omary Swalehe, Jean D' Amour Habagusenga, Stany Banzimana, Domina Asingizwe, Frank Chacky, Fabrizio Molteni","doi":"10.1080/20523211.2024.2308611","DOIUrl":"10.1080/20523211.2024.2308611","url":null,"abstract":"<p><strong>Background: </strong>Access to essential malaria commodities is a cornerstone in malaria control. However optimal availability and access to essential malaria commodities remain a challenge in Tanzania. Therefore, this study aimed to explore the factors affecting the accessibility of malaria commodities in Tanzania.</p><p><strong>Methods: </strong>This was a mixed-method cross-sectional study using both quantitative and qualitative approaches. Data were collected between February and March 2023 from health facilities, health facility staff, and patients.</p><p><strong>Results: </strong>Availability of malaria commodities in government health facilities was 100% for all items while in the private and faith-based facilities, this ranged from 10% to 80%. The reasons for stockouts in Government facilities were related to delayed and inadequate quantity delivery while in private facilities the main reason was the lack of cash for procurement. Both private facilities' clients and healthcare providers concurred that most people do not access complete treatment due to the high costs of prescribed medicines and poor stocking levels.</p><p><strong>Conclusion: </strong>The availability, hence the accessibility, of malaria commodities in private and faith-based health facilities is still sub-optimal. Logistic management needs to be improved to eliminate stockouts and malaria commodities high costs need a permanent solution.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing determinants of the availability of HIV tracer commodities in health facilities in Wakiso District, Uganda. 评估乌干达瓦基索地区医疗机构提供艾滋病毒示踪商品的决定因素。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-07 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2306846
Falisy Lule, Kalid Rajab, Stany Banzimana, Domina Asingizwe

Background: HIV/AIDS commodity stock-outs are still rampant in most African Countries causing treatment interruption, antiretroviral resistance, treatment failure, morbidity and mortality. Therefore, this study aimed at assessing the determinants of the availability of HIV Tracer Commodities in Health Facilities in Wakiso District, Uganda.

Methods: A descriptive cross-sectional design was conducted in 42 Health Facilities [HFs] offering HIV/AIDs services in Wakiso District, Uganda. Semi-structured questionnaire adapted from the Anti-Retroviral Therapy Supervision Performance and Recognition Strategy [ART SPARS] tool Version 2.0 | 2018111 was used to collect data.

Results: The majority of the HFs 28 [67%] had all the seven tracer commodities on the day of the visit. The majority of the HFs 33 [78.6%] were using Manual stock management tools that were fully updated. The availability of HIV tracer commodities was high in facilities that made timely ordering [AOR: 2.538, 95% CI: 2.126-3.304, p-value = 0.003] while the use of manual LMIS alone at the facility [AOR: 0.623, 95% CI: 0.131-0.958, p-value = 0.002] was associated with low availability.

Conclusion: This study indicated that 67% of health facilities visited had all HIV Tracer commodities on the day of the visit. ART commodity management should be computerised and orders made on time to ensure the availability of commodities.

背景:在大多数非洲国家,艾滋病毒/艾滋病商品缺货现象仍然十分严重,导致治疗中断、抗逆转录病毒耐药性、治疗失败、发病率和死亡率。因此,本研究旨在评估乌干达瓦基索地区医疗机构艾滋病毒示踪商品供应情况的决定因素:在乌干达瓦基索地区提供艾滋病毒/艾滋病服务的 42 家医疗机构中进行了描述性横断面设计。采用改编自抗逆转录病毒疗法监督绩效和认可策略[ART SPARS]工具2.0版|2018111的半结构化问卷收集数据:大多数重症监护室(HFs)有28家[67%]在访问当天拥有全部七种示踪商品。大多数试点医疗机构使用的《手册》库存管理工具已全面更新,有 33 家[78.6%]。在及时订购的医疗机构中,艾滋病示踪商品的可用性较高[AOR:2.538,95% CI:2.126-3.304,p 值 = 0.003],而仅使用手动库存管理信息系统的医疗机构[AOR:0.623,95% CI:0.131-0.958,p 值 = 0.002],其艾滋病示踪商品的可用性较低:这项研究表明,67% 的受访医疗机构在访问当天拥有所有的艾滋病示踪商品。抗逆转录病毒疗法商品管理应实现计算机化并及时订购,以确保商品的供应。
{"title":"Assessing determinants of the availability of HIV tracer commodities in health facilities in Wakiso District, Uganda.","authors":"Falisy Lule, Kalid Rajab, Stany Banzimana, Domina Asingizwe","doi":"10.1080/20523211.2024.2306846","DOIUrl":"10.1080/20523211.2024.2306846","url":null,"abstract":"<p><strong>Background: </strong>HIV/AIDS commodity stock-outs are still rampant in most African Countries causing treatment interruption, antiretroviral resistance, treatment failure, morbidity and mortality. Therefore, this study aimed at assessing the determinants of the availability of HIV Tracer Commodities in Health Facilities in Wakiso District, Uganda.</p><p><strong>Methods: </strong>A descriptive cross-sectional design was conducted in 42 Health Facilities [HFs] offering HIV/AIDs services in Wakiso District, Uganda. Semi-structured questionnaire adapted from the Anti-Retroviral Therapy Supervision Performance and Recognition Strategy [ART SPARS] tool Version 2.0 | 2018111 was used to collect data.</p><p><strong>Results: </strong>The majority of the HFs 28 [67%] had all the seven tracer commodities on the day of the visit. The majority of the HFs 33 [78.6%] were using Manual stock management tools that were fully updated. The availability of HIV tracer commodities was high in facilities that made timely ordering [AOR: 2.538, 95% CI: 2.126-3.304, <i>p</i>-value = 0.003] while the use of manual LMIS alone at the facility [AOR: 0.623, 95% CI: 0.131-0.958, <i>p</i>-value = 0.002] was associated with low availability.</p><p><strong>Conclusion: </strong>This study indicated that 67% of health facilities visited had all HIV Tracer commodities on the day of the visit. ART commodity management should be computerised and orders made on time to ensure the availability of commodities.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert consensus guidelines for community pharmacists in the management of diabetic peripheral neuropathy with a combination of neurotropic B vitamins. 为社区药剂师提供的专家共识指南:使用神经营养 B 族维生素组合治疗糖尿病周围神经病变。
IF 4.2 Q1 Health Professions Pub Date : 2024-02-07 eCollection Date: 2024-01-01 DOI: 10.1080/20523211.2024.2306866
Thanompong Sathienluckana, Sirinoot Palapinyo, Kitiyot Yotsombut, Ekgaluck Wanothayaroj, Pasiri Sithinamsuwan, Naeti Suksomboon

This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients' knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.

本共识指南供社区药剂师在糖尿病周围神经病变(DPN)管理中使用神经营养 B 族维生素组合。来自泰国的内分泌学、神经病学和药学等多学科团队通过文献综述和面对面会议,讨论并调整了社区药房环境中 DPN 管理的实用方案。五项主要声明作为 DPN 护理的共识建议得到了广泛认可。DPN 管理的目的包括减少症状和并发症的风险,尽量减少治疗方案的不良反应,以及提高患者对治疗策略的认识和依从性。应使用 "Douleur Neuropathique 4"(DN4)问卷的 7 个访谈项目进行初步筛查,以确定有可能患上 DPN 的患者。随后,应采用以患者为中心的药物和非药物治疗。一种有趣的方法是联合使用神经刺激性 B 族维生素,可作为单一疗法或联合疗法来控制 DPN 症状。联合疗法可能会产生协同效应,并提高患者的依从性。将在协调常规做法和国家要求的背景下进一步考虑该共识。
{"title":"Expert consensus guidelines for community pharmacists in the management of diabetic peripheral neuropathy with a combination of neurotropic B vitamins.","authors":"Thanompong Sathienluckana, Sirinoot Palapinyo, Kitiyot Yotsombut, Ekgaluck Wanothayaroj, Pasiri Sithinamsuwan, Naeti Suksomboon","doi":"10.1080/20523211.2024.2306866","DOIUrl":"10.1080/20523211.2024.2306866","url":null,"abstract":"<p><p>This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients' knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Policy and Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1